-

InVivo Therapeutics Announces Presentation at the Upcoming H.C Wainwright Virtual Global Investment Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries (SCIs), today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming H.C. Wainwright Virtual Global Investment Conference. The presentation is scheduled for Wednesday, September 16, 2020 at 11:00 am Eastern Time. A live webcast will be available at https://wsw.com/webcast/hcw7/nviv/1631915. Dr. Toselli will discuss recent company updates, including updates related to the Company’s ongoing INSPIRE 2.0 Study for acute thoracic SCI. In addition to the presentation, Dr. Toselli will also be available for one-on-one meetings with investors who are registered to attend the conference, which runs from September 14 – 16, 2020.

About InVivo Therapeutics

InVivo Therapeutics (Nasdaq: NVIV) is a clinical-stage biotechnology company focused on redefining the treatment of spinal cord injury. InVivo’s proprietary and investigational Neuro-Spinal Scaffold, based on technology licensed from Robert S. Langer’s lab at Massachusetts Institute of Technology, is in pivotal clinical studies for acute spinal cord injury. The company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Contacts

Investor Contact:
Bret Shapiro, Managing Partner
CORE IR
brets@coreir.com
(516) 222-2560

Industry:

InVivo Therapeutics Holdings Corp.

NASDAQ:NVIV
Release Versions
English

Contacts

Investor Contact:
Bret Shapiro, Managing Partner
CORE IR
brets@coreir.com
(516) 222-2560

More News From InVivo Therapeutics Holdings Corp.

InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCI), today announced topline results from the company’s INSPIRE 2.0 study, which was designed to evaluate the safety and probable benefit of InVivo’s investigational Neuro-Spinal Scaffold™, a bioresorbable scaffold-based device in development for patients with acute SCI. The study did no...

InVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

CAMBRIDGE, Mass--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has closed its previously announced registered direct offering for the sale and issuance of 154,000 shares of the Company’s common stock and pre-funded warrants to purchase up to 369,810 shares of common stock to a single healthcare-focused institutional investor. T...

InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the sale and issuance of 523,810 shares of the Company’s common stock (or pre-funded warrants in lieu thereof), in a registered direct offering priced at-the-market...
Back to Newsroom